WO2024252380 - BACTERIAL CELLS FOR CO-EXPRESSION IN THE YEAST
National phase entry is expected:
Publication Number
WO/2024/252380
Publication Date
12.12.2024
International Application No.
PCT/ID2023/000004
International Filing Date
01.12.2023
Title **
[English]
BACTERIAL CELLS FOR CO-EXPRESSION IN THE YEAST
[French]
EN VUE D'UNE CO-EXPRESSION DANS LA LEVURE
Applicants **
BADAN RISET DAN INOVASI NASIONAL (BRIN)
Gedung B.J. Habibie, Jl. M.H. Thamrin no.8,
Kebon Sirih, Menteng
Jakarta Pusat, 10340, ID
Inventors
HERAWATI, Neng
Pusat Riset Rekayasa Genetika - BRIN
Jl. Raya Jakarta-Bogor KM.46, Cibinong
Bogor, Jawa Barat 16911, ID
DESRIANI
Pusat Riset Rekayasa Genetika - BRIN
Jl. Raya Jakarta-Bogor KM.46, Cibinong
Bogor, Jawa Barat 16911, ID
Priority Data
P00202304974
06.06.2023
ID
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 938 | |
| EPO | Filing, Examination | 6459 | |
| Japan | Filing | 532 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2635 |
Total: 11139 USD
Abstract[English]
with the α-factor signal peptide under the control of the AOX1 promoter. The above process will result in recombinant plasmids containing the KEX2 ORF.[French]
avec le peptide signal du facteur α sous la commande du promoteur de l'AOX1. Le procédé susmentionné permet d'obtenir des plasmides recombinés contenant l'ORF KEX2.